HC Wainwright & Co. analyst Matthew Caufield reiterates Lyra Therapeutics (NASDAQ:LYRA) with a Neutral and maintains $2 price target.
- Headlines
- HC Wainwright & Co. Reiterates Neutral on Lyra Therapeutics, Maintains $2 Price Target
HC Wainwright & Co. Reiterates Neutral on Lyra Therapeutics, Maintains $2 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
08:29
The struggle to ensure the delivery of homes has achieved its set goals, and the Real Estate market shows signs of stabilizing after a decline.
08:15
The FAW Jiefang Group's Asia Vets expected functional safety process system has passed international authoritative certification.
FAW Jiefang Group-0.12%
08:07
EHang collaborates with China Transportation Information Technology Group to jointly layout the construction of aerial traffic digital and ground infrastructure and other low-altitude industry ecosystems.
EH-1.32%